Skip to main content

Drug Interactions between AccessPak for HIV PEP Basic and fostemsavir

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tenofovir fostemsavir

Applies to: AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil) and fostemsavir

ADJUST DOSE: Coadministration with fostemsavir may increase the plasma concentrations of tenofovir alafenamide fumarate (TAF). The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1/1B3- mediated hepatic uptake by temsavir, the active moiety of fostemsavir. Inhibition of breast cancer resistance protein (BCRP)-mediated intestinal and hepatic transport of TAF may also contribute. However, clinical trial data are lacking. This interaction has not been observed with tenofovir disoproxil fumarate (TDF). Coadministration of TDF with fostemsavir increased the peak plasma concentration (Cmax) and systemic exposure (AUC) of tenofovir by 18% and 19%, respectively, and is not considered clinically significant.

MANAGEMENT: Caution and clinical monitoring are recommended with concomitant use of fostemsavir and tenofovir alafenamide fumarate. Some authorities advise that the dose of TAF be reduced to 10 mg daily when coadministered with fostemsavir, although a 10 mg dose may not be commercially available for some TAF-containing products.

References (1)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Drug and food interactions

Minor

tenofovir food

Applies to: AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil)

Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.

References (1)
  1. (2001) "Product Information. Viread (tenofovir)." Gilead Sciences

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer